Page 22 - Astrazeneca

How a dosing error turned into lucky punch for AstraZeneca and Oxford

"The reason we had the half-dose is serendipity," Mene Pangalos, the head of AstraZeneca's non-oncology research and development, told Reuters

Oxford-AstraZeneca vaccine shows positive results, up to 90% efficacy

Data from global trials to be submitted to the Indian regulator by the end of December

Serum Institute to focus on supplying Oxford Covid vaccine to India first

Poonawalla said the company will be able to produce 400 million doses of AstraZeneca's vaccine by July 2021 and scale up further from there

Delighted at AstraZeneca vaccine's effectiveness: Adar Poonawalla

Serum Institute of India (SII) CEO Adar Poonawalla on Monday expressed happiness at pharma major AstraZeneca's announcement that its COVID-19 vaccine candidate has been found to be 70 per cent effective on average. AstraZeneca said one dosing regimen showed vaccine efficacy of 90 per cent when the vaccine was given as a half-dose followed by a full dose at least one month apart, while another dosing regimen showed 62 per cent efficacy when given as two full doses at least one month apart. "The combined analysis from both dosing regimens resulted in an average efficacy of 70 per cent," it added. In a tweet, Poonawalla said, "I am delighted to hear that, Covishield, a low-cost, logistically manageable & soon to be widely available, #COVID19 vaccine, will offer protection up to 90% in one type of dosage regime and 62% in the other dosage regime...". SII is currently conducting clinical trials of Oxford University-AstraZeneca's COVID-19 vaccine candidate in India. AstraZeneca also ...

Astra-Oxford Covid-19 vaccine works but doses could be in short supply

Pfizer and Moderna may have an initial advantage in dealing with manufacturing challenges, as their novel messenger RNA technology can be scaled up.

Vaccine highly effective in preventing Covid-19, says AstraZeneca

AstraZeneca says late-stage trials of its Covid-19 vaccine were highly effective'' in preventing disease.

AstraZeneca will have enough Covid-19 vaccine for 200 mn doses this year

The company plans to keep the "active" drug substance in stock while it awaited regulatory approval around the world

Covid-19: AstraZeneca delivers but can't match rivals, here's what we know

The Astra-Oxford vaccine on average prevented 70% of cases in large trials in the U.K. and Brazil

India to Brazil, Astra-Oxford vaccine is key to many nations' Covid plan

The Astra vaccine costs a fraction of the price set by Pfizer; it should be easier to deploy far and wide than other shots.

Oxford-AstraZeneca Covid-19 vaccine shows immune response in older adults

The vaccine causes few side effects and provokes a response in T-cells that target the virus within 14 days of the first dose and a protective antibody response within 28 days of the booster dose

Covid-19 vaccine unlikely before early or mid-2021: WHO Southeast Asia head

Even the front-runners among vaccine companies would take at least a few months to complete Phase-III trials and evaluate the efficacy and safety of individual vaccines

Coronavirus updates: 2nd wave in Maharashtra 'soon' & the vaccine challenge

The Maharashtra government has said that the the second wave of coronavirus is expected in the state in January-February based on what is happening in Europe

AstraZeneca's Covid-19 vaccine to begin clinical trials in China this year

AstraZeneca plans to start early and mid-stage clinical trials of its Covid-19 vaccine candidate in China this year, a senior executive said, as it prepares a global rollout of the vaccine

AstraZeneca beats Q3 sales estimate on strong demand; backs 2020 outlook

Product sales, which exclude payments from collaborations, rose 7 per cent to $6.52 billion for the three months ended September 30 on a constant-currency basis

Bharat Biotech's coronavirus vaccine may be launched in February

Moderna and AstraZeneca are close behind the largest US drugmaker and are likely to have early data on their vaccine candidates before the end of the year.

AstraZeneca to bring non-US vaccine data before FDA for emergency approval

If and when AstraZeneca reaches the first statistically reliable efficacy and safety results from those trials, based on more than 25,000 volunteers in total, it would present them to the US Food and

AstraZeneca Pharma India Q2 net profit up 83% at Rs 26.33 crore

Drug firm AstraZeneca Pharma India on Thursday reported an 83.48 per cent rise in its net profit at Rs 26.33 crore for the quarter ended September 2020. The company had posted a net profit of Rs 14.41 crore for the corresponding period of the previous fiscal, it said in a filing to the BSE. Revenue from operations stood at Rs 209.47 crore for the quarter under consideration. It was Rs 208.48 crore for the same period a year ago, it added. Shares of AstraZeneca Pharma India closed at Rs4,295.80per scrip on the BSE, up 0.40 per cent from their previous close.

Britain prepares for Covid-19 vaccine as Oxford forecasts result this year

There are more than 200 candidates under development and the vaccine being developed by Oxford and licensed to British drugmaker AstraZeneca is seen as a front-runner

UK starts accelerated review for AstraZeneca's potential Covid-19 vaccine

"We confirm the MHRA's (Medicines and Healthcare Products Regulatory Agency) rolling review of our potential Covid-19 vaccine," an AstraZeneca spokesman said

UK starts real-time review of Moderna's Covid-19 vaccine candidate

Moderna said earlier this month it was going to apply for real-time reviews of its experimental Covid-19 vaccine to Europe, following rolling reviews of shots of its rivals Pfizer Inc and AstraZeneca